A detailed history of Parallax Volatility Advisers, L.P. transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Parallax Volatility Advisers, L.P. holds 7,494 shares of VRTX stock, worth $3.38 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
7,494
Previous 7,556 0.82%
Holding current value
$3.38 Million
Previous $3.54 Million 1.58%
% of portfolio
0.01%
Previous 0.01%

Shares

26 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$460.0 - $505.78 $28,520 - $31,358
-62 Reduced 0.82%
7,494 $3.49 Million
Q2 2024

Aug 14, 2024

SELL
$392.81 - $485.53 $552,290 - $682,655
-1,406 Reduced 15.69%
7,556 $3.54 Million
Q1 2024

May 15, 2024

BUY
$407.69 - $446.08 $281,306 - $307,795
690 Added 8.34%
8,962 $3.75 Million
Q4 2023

Feb 14, 2024

BUY
$343.0 - $410.68 $2.84 Million - $3.4 Million
8,272 New
8,272 $3.37 Million
Q2 2023

Aug 14, 2023

SELL
$314.42 - $351.91 $93,697 - $104,869
-298 Reduced 83.24%
60 $21,000
Q1 2023

May 15, 2023

BUY
$283.23 - $323.1 $84,402 - $96,283
298 Added 496.67%
358 $112,000
Q4 2022

Feb 14, 2023

SELL
$285.76 - $321.48 $303,477 - $341,411
-1,062 Reduced 94.65%
60 $17,000
Q3 2022

Nov 14, 2022

BUY
$273.83 - $305.53 $307,237 - $342,804
1,122 New
1,122 $324,000
Q3 2021

Nov 15, 2021

BUY
$181.39 - $202.99 $911,303 - $1.02 Million
5,024 New
5,024 $911,000
Q3 2021

Nov 15, 2021

SELL
$181.39 - $202.99 $640,850 - $717,163
-3,533 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$187.49 - $221.1 $662,402 - $781,146
3,533 New
3,533 $712,000
Q1 2021

May 14, 2021

SELL
$207.02 - $241.31 $6,624 - $7,721
-32 Reduced 10.36%
277 $60,000
Q1 2021

May 14, 2021

SELL
$207.02 - $241.31 $57,344 - $66,842
-277 Closed
0 $0
Q4 2020

Feb 16, 2021

BUY
$207.01 - $276.09 $63,966 - $85,311
309 New
309 $73,000
Q4 2020

Feb 16, 2021

SELL
$207.01 - $276.09 $16,353 - $21,811
-79 Closed
0 $0
Q3 2020

Nov 13, 2020

SELL
$255.65 - $303.1 $375,805 - $445,557
-1,470 Reduced 94.9%
79 $21,000
Q2 2020

Aug 14, 2020

BUY
$225.48 - $295.8 $253,890 - $333,070
1,126 Added 266.19%
1,549 $450,000
Q1 2020

May 15, 2020

SELL
$199.77 - $247.81 $163,212 - $202,460
-817 Reduced 65.89%
423 $101,000
Q4 2019

Feb 14, 2020

SELL
$166.71 - $223.91 $264,235 - $354,897
-1,585 Reduced 56.11%
1,240 $271,000
Q3 2019

Nov 14, 2019

BUY
$166.23 - $187.09 $469,433 - $528,342
2,824 Added 282400.0%
2,825 $478,000
Q2 2019

Aug 14, 2019

SELL
$164.61 - $190.37 $640,497 - $740,729
-3,891 Reduced 99.97%
1 $0
Q4 2018

Feb 14, 2019

BUY
$151.91 - $192.21 $511,480 - $647,171
3,367 Added 641.33%
3,892 $645,000
Q3 2018

Nov 14, 2018

SELL
$167.73 - $192.74 $427,376 - $491,101
-2,548 Reduced 82.92%
525 $101,000
Q2 2018

Aug 14, 2018

BUY
$145.72 - $169.96 $447,797 - $522,287
3,073 New
3,073 $522,000
Q1 2018

May 15, 2018

SELL
$151.6 - $177.13 $897,472 - $1.05 Million
-5,920 Closed
0 $0
Q4 2017

Feb 14, 2018

BUY
$137.28 - $155.55 $812,697 - $920,856
5,920
5,920 $887,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $116B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Parallax Volatility Advisers, L.P. Portfolio

Follow Parallax Volatility Advisers, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Parallax Volatility Advisers, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Parallax Volatility Advisers, L.P. with notifications on news.